Thyrotropin, Hyperthyroidism, and Bone Mass.

Se-Min Kim, Vitaly Ryu, Sari Miyashita, Funda Korkmaz, Daria Lizneva, Sakshi Gera, Rauf Latif, Terry F Davies, Jameel Iqbal, Tony Yuen, Mone Zaidi

The Journal of clinical endocrinology and metabolism 2021 Nov 19

filter terms:

Thyrotropin (TSH), traditionally seen as a pituitary hormone that regulates thyroid glands, has additional roles in physiology including skeletal remodeling. Population-based observations in people with euthyroidism or subclinical hyperthyroidism indicated a negative association between bone mass and low-normal TSH. The findings of correlative studies were supported by small intervention trials using recombinant human TSH (rhTSH) injection, and genetic and case-based evidence. Genetically modified mouse models, which disrupt the reciprocal relationship between TSH and thyroid hormone, have allowed us to examine an independent role of TSH. Since the first description of osteoporotic phenotype in haploinsufficient Tshr +/- mice with normal thyroid hormone levels, the antiosteoclastic effect of TSH has been documented in both in vitro and in vivo studies. Further studies showed that increased osteoclastogenesis in Tshr-deficient mice was mediated by tumor necrosis factor α. Low TSH not only increased osteoclastogenesis, but also decreased osteoblastogenesis in bone marrow-derived primary osteoblast cultures. However, later in vivo studies using small and intermittent doses of rhTSH showed a proanabolic effect, which suggests that its action might be dose and frequency dependent. TSHR was shown to interact with insulin-like growth factor 1 receptor, and vascular endothelial growth factor and Wnt pathway might play a role in TSH's effect on osteoblasts. The expression and direct skeletal effect of a biologically active splice variant of the TSHβ subunit (TSHβv) in bone marrow-derived macrophage and other immune cells suggest a local skeletal effect of TSHR. Further studies of how locally secreted TSHβv and systemic TSHβ interact in skeletal remodeling through the endocrine, immune, and skeletal systems will help us better understand the hyperthyroidism-induced bone disease. © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Citation

Se-Min Kim, Vitaly Ryu, Sari Miyashita, Funda Korkmaz, Daria Lizneva, Sakshi Gera, Rauf Latif, Terry F Davies, Jameel Iqbal, Tony Yuen, Mone Zaidi. Thyrotropin, Hyperthyroidism, and Bone Mass. The Journal of clinical endocrinology and metabolism. 2021 Nov 19;106(12):e4809-e4821